Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Atomoxetine's Effect on Societal Costs in Sweden

Myren, Karl-Johan ; Thernlund, Gunilla LU ; Nylen, Asa ; Schacht, Alexander and Svanborg, Par (2010) In Journal of Attention Disorders 13(6). p.618-628
Abstract
Objective: To compare societal costs between patients treated with atomoxetine and placebo in Sweden. Method: Ninety-nine pediatric ADHD patients were randomized to a 10-week double-blind treatment with atomoxetine (n = 49) or placebo (n = 50). All parents received four sessions of psycho-education. Parents filled out a resource utilization questionnaire covering the 10 weeks prior to treatment and the 10-week on-treatment period. Published unit costs/prices were used to calculate costs. Results: Mean on-treatment costs in the atomoxetine group (SEK [Swedish Krona] 4,558) were significantly lower compared with placebo (SEK 7,684) after adjusting for baseline costs and site (p = .007). All 99 patients entered an open atomoxetine extension... (More)
Objective: To compare societal costs between patients treated with atomoxetine and placebo in Sweden. Method: Ninety-nine pediatric ADHD patients were randomized to a 10-week double-blind treatment with atomoxetine (n = 49) or placebo (n = 50). All parents received four sessions of psycho-education. Parents filled out a resource utilization questionnaire covering the 10 weeks prior to treatment and the 10-week on-treatment period. Published unit costs/prices were used to calculate costs. Results: Mean on-treatment costs in the atomoxetine group (SEK [Swedish Krona] 4,558) were significantly lower compared with placebo (SEK 7,684) after adjusting for baseline costs and site (p = .007). All 99 patients entered an open atomoxetine extension phase. Both groups had numerical reductions in direct and indirect costs while on atomoxetine treatment during the extension phase. The atomoxetine medication costs were offset by the reductions in direct nonmedical and indirect costs. Conclusions: These data provide preliminary evidence that atomoxetine together with parental psycho education reduces nonmedication costs associated with ADHD in Sweden. (J. of Att. Dis. 2010; 13(6) 618-628) (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
health care costs, ADHD, atomoxetine, societal costs
in
Journal of Attention Disorders
volume
13
issue
6
pages
618 - 628
publisher
SAGE Publications
external identifiers
  • wos:000277146700007
  • scopus:77951790512
  • pmid:19365087
ISSN
1557-1246
DOI
10.1177/1087054709332163
language
English
LU publication?
yes
id
bf91954d-e79e-4c6f-ba48-e94235eff394 (old id 1619419)
date added to LUP
2016-04-01 10:43:38
date last changed
2022-01-26 01:58:23
@article{bf91954d-e79e-4c6f-ba48-e94235eff394,
  abstract     = {{Objective: To compare societal costs between patients treated with atomoxetine and placebo in Sweden. Method: Ninety-nine pediatric ADHD patients were randomized to a 10-week double-blind treatment with atomoxetine (n = 49) or placebo (n = 50). All parents received four sessions of psycho-education. Parents filled out a resource utilization questionnaire covering the 10 weeks prior to treatment and the 10-week on-treatment period. Published unit costs/prices were used to calculate costs. Results: Mean on-treatment costs in the atomoxetine group (SEK [Swedish Krona] 4,558) were significantly lower compared with placebo (SEK 7,684) after adjusting for baseline costs and site (p = .007). All 99 patients entered an open atomoxetine extension phase. Both groups had numerical reductions in direct and indirect costs while on atomoxetine treatment during the extension phase. The atomoxetine medication costs were offset by the reductions in direct nonmedical and indirect costs. Conclusions: These data provide preliminary evidence that atomoxetine together with parental psycho education reduces nonmedication costs associated with ADHD in Sweden. (J. of Att. Dis. 2010; 13(6) 618-628)}},
  author       = {{Myren, Karl-Johan and Thernlund, Gunilla and Nylen, Asa and Schacht, Alexander and Svanborg, Par}},
  issn         = {{1557-1246}},
  keywords     = {{health care costs; ADHD; atomoxetine; societal costs}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{618--628}},
  publisher    = {{SAGE Publications}},
  series       = {{Journal of Attention Disorders}},
  title        = {{Atomoxetine's Effect on Societal Costs in Sweden}},
  url          = {{http://dx.doi.org/10.1177/1087054709332163}},
  doi          = {{10.1177/1087054709332163}},
  volume       = {{13}},
  year         = {{2010}},
}